SCANCELL HOLDINGS PLC (SCLP) — Clinical and Corporate Update

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to the SCANCELL HOLDINGS PLC Clinical and Corporate Update. Simply type in your questions and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review your questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll. And I would now like to hand you over to CEO Phil Luellier. Good morning to you. Good morning, and welcome to everybody joining the SCANCELL update. I'm Phil Luellier, CEO of SCANCELL. And today, I'm joined by our CMO, Namine, but also later our CFO, Seth, join for the Q and A. As an organization, we are building strong momentum across key areas of the business. Today, we want to give you an update on two of those key areas: the clinical program, the scope study, an update on the design and where we are with the scope study, but also a corporate update. And today, we're announcing the formation of a wholly owned subsidiary company of SCANCELL, GlyMab Therapeutics, which will house our antibody portfolio and enable us to unlock greater value in the portfolio by taking this step. We'll come back and talk to you about this later in the presentation. Before I hand over to Namine, I just want to remind you of where we are with our key timelines. We continue to make strong momentum in our SCOPE study, but also in the MODIFY study. We told you that we would make key announcements of data in the middle of the year and we are on track to do that. And today we're announcing that we will be sharing data later in July for the first cohorts of the SCOPE study and we are on track to release data for cohort four towards the end of the year. The MODIFY study with MODY-one in renal ...